Skip to main content
SpringerLink
Log in

Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer

An investigation of 117 pelvic lymph nodes

  • Original Article
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

Abstract

Background

The optimal radiotherapy regimen is not yet defined in the setting of oligorecurrent prostate cancer (oligorPC). There is evidence of high variability in treatment protocols among different centers worldwide, and no international consensus guidelines on treatment volumes, radiation schedules, and techniques. The purpose of the present retrospective study is to evaluate the efficacy and safety of involved-pelvic-node stereotactic body radiotherapy (SBRT) for oligorPC.

Materials and methods

Patients with pelvic node oligorPC following primary surgery, radical radiotherapy, or salvage radiotherapy for biochemical or local relapse of prostate cancer who underwent involved-node SBRT with biological effective dose (BED) > 100 Gy, with or without concurrent and adjuvant androgen deprivation therapy (ADT), were retrospectively evaluated. Biochemical progression-free survival (bPFS), distant progression-free survival (DPFS), overall survival (OS), possible prognostic factors, and toxicity outcomes were investigated.

Results

From November 2012 to December 2019, 74 patients fitted the selection criteria. A total of 117 lesions were treated. Median follow-up was 31 months (range 6–89). Concurrent ADT was administered in 58.1% of patients. The 1‑year, 2‑year, and 3‑year DPFS was 77%, 37%, and 19%, respectively; the 1‑year, 2‑year, and 3‑year OS was 98%, 98%, and 95%, respectively. The presence of a single target lesion was associated with a statistically significant impact on OS. No in-field recurrence occurred. Patients who reached early prostate-specific antigen (PSA) nadir (< 3 months after SBRT) had a lower 3‑year survival (p = 0.004). The value of PSA nadir after SBRT and the time between primary treatment and SBRT had an impact on bPFS. Concomitant ADT was associated with improved DPFS. No acute or early late (> 6 months) genitourinary and gastrointestinal adverse events of any grade were reported, albeit with relatively short median follow-up.

Conclusion

SBRT is a safe and effective treatment for oligorPC, with a 100% local control rate in our series. It is not possible to clearly assess the opportunity to postpone ADT prescription in patients with two or more nodal metastases. The number of secondary lesions, time-to-nadir PSA, PSA nadir value, and the time interval between primary treatment and SBRT were identified as prognostic factors. Future prospective randomized studies are desirable to better understand the still open questions regarding the oligorecurrent prostate cancer state.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Torre LA, Siegel R, Ward EM et al (2016) global cancer incidence and mortality rate and trends: an update. Cancer Epidemiol Biomarkers Prev 25(1):16–27

    Article  Google Scholar 

  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492

    Article  PubMed  Google Scholar 

  3. Italian Medical Oncology Association (2018) Italian cancer registry by the Italian Medical Oncology Association

    Google Scholar 

  4. Parker WP, Davis BJ, Park SS et al (2017) Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C‑11 choline positron emission tomography/computed tomography: a nomogram for predicting extrapelvic disease. Eur Urol 71:340–348

    Article  Google Scholar 

  5. Alongi F, Arcangeli S, Filippi AR et al (2012) Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17(8):1100–1107

    Article  Google Scholar 

  6. Calais J, Czernin J, Cao M et al (2018) 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med 59:230–237

    Article  CAS  Google Scholar 

  7. Devos G, De Meerleer G, Joniau S (2019) Have we entered the era of imaging before salvage treatment for recurrent prostate cancer? Eur Urol 76:265–267

    Article  Google Scholar 

  8. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG et al (2016) Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937

    Article  Google Scholar 

  9. Lancia A, Zilli T, Achard V et al (2019) Oligometastatic prostate cancer: the game is afoot. Cancer Treat Rev 73:84–90

    Article  Google Scholar 

  10. Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650

    Article  Google Scholar 

  11. Panje C, Zilli T, Pra AD et al (2019) Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol 14:177

    Article  Google Scholar 

  12. De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G et al (2017) Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int 120:815–821

    Article  Google Scholar 

  13. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10

    Article  CAS  Google Scholar 

  14. Achard V, Bottero M, Rouzaud M et al (2020) Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review. Acta Oncol 59(10):1224–1234. https://doi.org/10.1080/0284186X.2020.1775291

    Article  PubMed  Google Scholar 

  15. De Bruycker A, Spiessens A, Dirix P et al (2020) PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer 20(1):406

    Article  Google Scholar 

  16. Ost P, Jereczek-Fossa BA, As NV et al (2016) Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol 69:9–12

    Article  Google Scholar 

  17. Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650

    Article  Google Scholar 

  18. Pasqualetti F, Panichi M, Sollini M et al (2020) (18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with current oligometastatic prostate cancer. Eur J Nucl Med Mol Imaging 47:185–191

    Article  Google Scholar 

  19. Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence:a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446–453

    Article  CAS  Google Scholar 

  20. Siva S, Bressel M, Murphy DG et al (2018) Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74:455–462

    Article  Google Scholar 

  21. Jereczek-Fossa BA, Fanetti G, Fodor C et al (2017) Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer 15:e623–e632

    Article  Google Scholar 

  22. Decaestecker K, De Meerleer G, Lambert B et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:135

    Article  Google Scholar 

  23. Jereczek-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82:889–897

    Article  Google Scholar 

  24. Casamassima F, Masi L, Menichelli C et al (2011) Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 97:49–55

    Article  CAS  Google Scholar 

  25. Kneebone A, Hruby G, Ainsworth H et al (2018) Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol 1:531–537

    Article  Google Scholar 

  26. Soldatov A, von Klot CAJ, Walacides D et al (2019) Patterns of progression after 68Ga-PSMA-ligand PET/CT-guided radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 103:95–104

    Article  Google Scholar 

  27. Perera M, Papa M, Roberts M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403–417

    Article  Google Scholar 

  28. Berkovic P, De Meerleer G, Delrue L et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation, therapy. Clin Genitourin Cancer 11:27–32

    Article  Google Scholar 

  29. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 52:1622–1628

    Article  CAS  Google Scholar 

  30. Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B et al (2017) Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus 3:538–544

    Article  Google Scholar 

  31. Carrie C, Hasbini A, de Laroche G et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostatespecific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17:747–756

    Article  CAS  Google Scholar 

  32. Shipley WU, Seiferheld W, Lukka HR et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417–428

    Article  Google Scholar 

  33. Pollack A, Balogh AG, Low D et al (2018) Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiation therapy: the NRG Oncology/RTOG 0534 SPPORT trial. ASTRO 102:1605

    Google Scholar 

  34. Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453

    Article  CAS  Google Scholar 

  35. Park Y, Park HJ, Jang WI, Jeong BK, Kim H‑J, Chang AR (2018) Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean Radiation Oncology group study 15-01). Radiat Oncol 13(1):230

    Article  CAS  Google Scholar 

  36. Sasaki T, Onishi T, Hoshina A (2011) Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis 14(3):248–252

    Article  CAS  Google Scholar 

  37. Hori S, Jabbar T, Kachroo N et al (2011) Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 137:235–241

    Article  CAS  Google Scholar 

  38. Arai Y, Yoshiki T, Yoshida O (1990) Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 144:1415–1419

    Article  CAS  Google Scholar 

  39. Yeung F, Li X, Ellett J et al (2000) Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 275:40846–40855

    Article  CAS  Google Scholar 

  40. Onishi T, Yamakawa K, Franco OE et al (2001) Mitogen-activated protein kinase pathway is involved in alpha 6 integrin gene expression in androgen-independent prostate cancer cell: role of proximal Sp1 consensus sequence. Biochim Biophys Acta 14728:1–1

    Google Scholar 

  41. Choueiri TK, Xie W, d’Amico AV et al (2009) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115:981–987

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

    Salvatore Cozzi MD, Giorgia Timon MD, Gladys Blandino MD, Moana Manicone MD, Maria Paola Ruggieri, Patrizia Ciammella MD & Cinzia Iotti MD

  2. Medical Physics Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

    Andrea Botti MD

  3. Department of Radiation Oncology Shohadaye Haft-e-Tir Hospital, Iran University of Medical Science, Teheran, Iran

    Masoumeh Najafi MD

  4. Radiation Oncology Unit, S. Luca Hospital, Healtcare Company Tuscany Nord Ovest, Lucca, Italy

    Lilia Bardoscia MD

Authors
  1. Salvatore Cozzi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Botti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giorgia Timon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gladys Blandino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masoumeh Najafi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Moana Manicone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lilia Bardoscia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Paola Ruggieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patrizia Ciammella MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cinzia Iotti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salvatore Cozzi MD.

Ethics declarations

Conflict of interest

S. Cozzi, A. Botti, G. Timon, G. Blandino, M. Najjafi, M. Manicone, L. Bardoscia, M.P. Ruggieri, P. Ciammella, and C. Iotti declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cozzi, S., Botti, A., Timon, G. et al. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer. Strahlenther Onkol 198, 700–709 (2022). https://doi.org/10.1007/s00066-021-01871-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-021-01871-5

Keywords

Search

Navigation